|
|
|
|
TopAbstracts in Vascular Disorders 03/18/2010
TopAbstracts in Vascular Disorders are the abstracts most highly rated/most read by nearly 300,000 physicians who received a Doctor's Guide newsletter or visited a website Powered by Doctor's Guide in the past 14 days.Over 2000 peer-reviewed journals are...
|
|
|
Follow-up of Phase I Trial of Adalimumab and Rosiglitazone in FSGS: III. Report of the FONT Study Group
Antifibrotic therapy for a defined period of time may be a viable strategy to pr Follow-up of Phase I Trial of Adalimumab and Rosiglitazone in FSGS: III.Report of the FONT Study Group.
|
|
|
Letter Urging Ban of Propoxyphene (Darvon), Sibutramine (Meridia) and Rosiglitazone (Avandia) (HRG Publication
-Consumer advocacy group Public Citizen has posted a letter on its website addressed to the FDA calling for the agency to ban Avandia, Darvon and Meridia.March 8, 2010 Margaret A. Hamburg, M.D., Commissioner Joshua Sharfstein, M.D., Principal Deputy...
|
|
|
Rosiglitazone (Avandia, Avandamet)
is an effective treatment for patients with type 2 (ie non-insulin-dependent) diabetes and belongs to a class of drugs called thiazolidinediones (also called glitazones).Concerns about the cardiovascular safety of rosiglitazone led to a Europe-wide review of...
|
|
|
Obesity and Diabetes Risk Factors: Investigators at Sahlgrenska University have published new data on obesity and diabetes risk factors
Today's Medical & Research News Investigators at Sahlgrenska University have published new data on March 5th, 2010 Printer-Friendly Version City:Gothenburg Country:Sweden Adipogenesis Bone Fractures Diabetes Endocrinology Fibrinolytic Agent Hypoglycemic...
|
|
|
Cedars-Sinai Heart Institute Cardiologist Sanjay Kaul, M.D. Co-Authors Statement On Safety Of Diabetes Drugs
A Cedars-Sinai Heart Institute cardiologist co-authored the joint science advisory issued by the American Heart Association and the American College of Cardiology that calls for close monitoring of patients taking certain blood sugar-lowering drugs.Sanjay...
|
|
|
Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. The Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in Diabetes Patients With Cardio
Gerstein HC et al.Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. The Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in...
|
|
|
Cedars-Sinai Heart Institute Cardiologist Sanjay Kaul, M.D. Co-Authors Statement on Safety of Diabetes Drugs
Source: Cedars-Sinai Medical Center Newswise A Cedars-Sinai Heart Institute cardiologist co-authored the joint science advisory issued by the American Heart Association and the American College of Cardiology that calls for close monitoring of patients taking...
|
|
|
Santa Clara Co. Sues Glaxo Over Diabetes Drug
Required fields are marked with an asterisk(*) Recipient E-mail:* Your Name:* Your E-mail:* Add a Message: Send me a copy of this e-mail.Type the characters in this picture:* The information you provide will be used only to send the requested e-mail and will...
|
|
|
Diabetic drug warning
KUALA LUMPUR: Thirty-three Malaysians have filed complaints with the Health Ministry about adverse effects after taking an anti diabetic agent, rosiglitazone, also known as Avandia.Two of the reports were linked to myocardial ischaemia, a heart condition...
|
|
|
Diabetic drug warning
KUALA LUMPUR: Thirty-three Malaysians have filed complaints with the Health Ministry about adverse effects after taking an antidiabetic agent, rosiglitazone, also known as Avandia.Two of the reports were linked to myocardial ischaemia, a heart condition...
|
|
|
FDA Drug Safety Communication & American Heart Association Statement
MENAFN Press - 01/03/2010 (MENAFN Press) Rockville, USA, Sunday, February 28th 2010 [ME NewsWire]: The U.S.Food and Drug Administration (FDA) has issued a communication statement on 22nd February, 2010, based on its ongoing large, long-term clinical study...
|
|
|
FDA Reviewers Urge Pulling Rosiglitazone
Two FDA reviewers have recommended that the diabetes drug rosiglitazone (Avandia) be pulled from the market because of its link to major cardiac events.The recommendations were released as part of a report from the U.S. Senate Finance Committee on the...
|
|
|
GlaxoSmithKline Pharmaceuticals Limited Response to Recent Media Reports on Rosiglitazone
Source : GlaxoSmithKline Pharmaceuticals Limited (Business Wire India) Category : BUSINESS, LEISURE, HEALTH U.S.Senate Committee on Finance issued a report on GlaxoSmithKline's Avandia (rosiglitazone), on Saturday, February 20, 2010, which was reported in...
|
|
|
GlaxoSmithKline Pharmaceuticals Limited Response to Recent Media Reports on Rosiglitazone
Source : GlaxoSmithKline Pharmaceuticals Limited U.S.Senate Committee on Finance issued a report on GlaxoSmithKlines Avandia (rosiglitazone), on Saturday, February 20, 2010, which was reported in some sections of the media. Today, GlaxoSmithKline...
|
|
|
GlaxoSmithKline Pharmaceuticals response to recent media reports on Rosiglitazone
Mumbai U.S.Senate Committee on Finance issued a report on GlaxoSmithKlines Avandia (rosiglitazone), on Saturday, February 20, 2010, which was reported in some sections of the media. Today, GlaxoSmithKline Pharmaceuticals Limited (GSK) issued the following...
|
|
|
FDA Offers Docs Guidance on Rosiglitazone as Safety Review Nears Completion
Senate Committee Critical of Agency, GSK The FDA is recommending that patients continue taking the diabetes medication rosiglitazone, unless told otherwise by their physicians, as the agency continues to look at the risks and benefits of using rosiglitazone to...
|
|
|
GlaxoSmithKline Pharmaceuticals response to recent media reports on Rosiglitazone
Mumbai: U.S.Senate Committee on Finance issued a report on GlaxoSmithKlines Avandia (rosiglitazone), on Saturday, February 20, 2010, which was reported in some sections of the media. Today, GlaxoSmithKline Pharmaceuticals Limited (GSK) issued the following...
|
|
|
Cardiology Groups Stand by Embattled Diabetes Drug Rosiglitazone
By Crystal Phend, Senior Staff Writer, MedPage Today Published: February 24, 201 Cardiology Groups Stand by Embattled Diabetes Drug Rosiglitazone.
|
|
|
GlaxoSmithKline Fires Back in Defense of Rosiglitazone
_ GlaxoSmithKline Fires Back in Defense of Rosiglitazone.
|
|
|
GlaxoSmithKline Fires Back in Defense of Rosiglitazone
In its response, the company states it has been "proactive in investigating the safety data" of rosiglitazone and is critical of the Senate report that ignores GlaxoSmithKline Fires Back in Defense of Rosiglitazone.
|
|
|
Pharmacodynamic Effects of Rosiglitazone in Nondiabetic Patients with Metabolic Syndrome
Aquilante CL et al.Rosiglitazone had beneficial effects on adiponectin concentrations without significantly affecting other components of the metabolic syndrome phenotype. Pharmacodynamic Effects of Rosiglitazone in Nondiabetic Patients with...
|
|
|
GSK salvages diabetes drug, for now
Mumbai: Even as the storm over heart risks posed by diabetes drug rosiglitazone continues unabated, drugmaker GSK Plcs last-ditch effort at salvaging the blockbuster drug have borne fruit.The US Food and Drug Administration (FDA) the worlds foremost body...
|
|
|
FDA Drug Safety Communication: Ongoing review of Avandia (rosiglitazone) and cardiovascular safety
The U.S.Food and Drug Administration (FDA) is reviewing data, submitted in August 2009, from a large, long-term clinical study on possible risks with the diabetes drug, Avandia* (rosiglitazone). The clinical study, called the Rosiglitazone Evaluated...
|
|
|
Experts Debate Future of Rosiglitazone in the Wake of Critical Senate Report
In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site.To find out how to adjust your browser settings to accept cookies, please click here. Medscape uses cookies to customize the site based on the information...
|
